Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > VisEn Announces Launch of Novel MMPSense Fluorescence Molecular Imaging Probe

Abstract:
-VisEn's Expanding Probe Portfolio Broadens Molecular Imaging Applications in Key Areas of Disease Research and Drug Development-

VisEn Announces Launch of Novel MMPSense Fluorescence Molecular Imaging Probe

WOBURN, MA | Posted on June 8th, 2007

VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the market launch of its MMPSense(TM) molecular imaging probe for real time imaging of matrix metalloproteinase (MMP) related activities in vivo. The launch further expands the company's proprietary molecular imaging probe and system product platforms to now even more broadly enable real-time imaging of molecular and biologic activity in vivo, including ranges of protease activities, angiogenesis, bone generation, vascular permeability, and inflammatory responses. By imaging and quantifying disease-related biological activities and therapeutic interventions in vivo, VisEn technology platforms enable expanded areas of research, increasingly efficient drug development, and advanced personalized clinical medicine into the future.

The VisEn MMPSense(TM) probe, developed from the Company's proprietary fluorescence imaging probe platforms, is an activatible in vivo fluorescence probe capable of imaging MMP activity in tumors and other sites of inflammation in vivo. In its non-active state, the probe is not fluorescent, but it emits strong fluorescence in response to MMP activity in vivo. According to the National Cancer Institute, MMPs are a group of enzymes that can break down proteins, such as collagen, that are normally found in the spaces between cells in tissues (i.e., extracellular matrix proteins). It is known that MMP activity is involved in many disease-related phenomena, including cancer propagation, invasion and metastasis, inflammation, host response, and in areas of cardiovascular disease. On May 2 of this year, VisEn Medical and its exclusive distribution partner in Asia, Olympus Corporation, announced the launch of MMPSense as well as VisEn's nanoparticle- based AngioSpark and AminoSpark molecular imaging probes, in Japan and other key Asian markets.

"Today's MMPSense product launch marks a significant advance in our drive to provide a complete package of translational molecular imaging solutions for measuring and quantifying disease progression and drug effect in vivo," said Kirtland G. Poss, President and CEO of VisEn Medical. "Our partners in drug development and clinical research worldwide can now access these important new tools that will help the whole field better understand, define and treat molecular targets and disease processes in an unprecedented fashion."

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Probe Portfolio and its Fluorescence Molecular Tomographic Imaging Systems (FMT), provide the industry's most robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers in vivo. VisEn probes are designed to be compatible with a range of fluorescence imaging systems, including planar fluorescence imaging systems, intravital microscopes, and VisEn's FMT tomographic imaging system.

Additional product information can be obtained by calling Customer Support at VisEn Medical: 781-932-6875, ext. 315; or via email at: ; or at http://www.visenmedical.com/ .

####

About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School. VisEn is developing the industry's highest performing fluorescence molecular imaging technology platforms, from research through medicine. The Company also works directly with its partners to design ranges of tailored probes and applications that are targeted to their specific research areas. VisEn recently announced a multi-year joint research and development program with Merck & Co to develop and apply a range of fluorescence imaging agents for real-time imaging of key disease biomarkers in vivo. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures and The Bollard Group.

For more information, please click here

Contacts:
Customer Support
VisEn Medical
781-932-6875, ext. 315

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New non-invasive method can detect Alzheimer's disease early: MRI probe technology shows brain toxins in living animals for first time December 22nd, 2014

Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014

Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Announcements

New non-invasive method can detect Alzheimer's disease early: MRI probe technology shows brain toxins in living animals for first time December 22nd, 2014

Piezoelectricity in a 2-D semiconductor: Berkeley Lab researchers discovery of piezoelectricty in molybdenum disulfide holds promise for future MEMS December 22nd, 2014

Quantum physics just got less complicated December 22nd, 2014

Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014

Tools

New non-invasive method can detect Alzheimer's disease early: MRI probe technology shows brain toxins in living animals for first time December 22nd, 2014

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

ORNL microscopy pencils patterns in polymers at the nanoscale December 17th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE